Chief Scientific Officer
Join our CSO, Anne Phelan, to explore advances in machine learning and artificial intelligence for target discovery.
The complexity of human disease poses significant challenges in the translation of basic research into safe and effective therapies, with at least 50% of drugs failing in Phase II and Phase III trials for lack of efficacy.
In this talk, Dr Anne Phelan will discuss BenevolentAI’s approach to tackling this complexity. BenevolentAI has built a comprehensive knowledge graph incorporating and capitalising on many orthogonal data modalities, to build a detailed mechanistic representation of the dysregulated processes that underlie human disease. Powerful AI and ML tools are used to interrogate this corpus of knowledge, to hypothesise novel biological targets of potential therapeutic value for any disease of interest. These hypotheses are experimentally validated in physiologically relevant human patient-derived cell based systems, before entering the BenevolentAI drug discovery portfolio. In this talk, Dr Phelan will describe the current status of AI in drug discovery and her vision for future technological solutions that will help to overcome some of the key challenges required to affect change across the entire R&D value chain.
This Royal Society conference brings together stakeholders from industry and academia to explore advances in machine learning and artificial intelligence for biological research, drug discovery and medicine. The event will also include a keynote address from Dr Demis Hassabis CBE FREng FRS (DeepMind).
Back to events